Abstract
CAB-LA administered every two months was recently approved in the US as PrEP for individuals at risk of acquiring HIV-1 infection based on the HPTN 083 and 084 studies, which both demonstrated superior reduction in HIV-1 acquisition compared with daily oral FTC/TDF in men who have sex with men (MSM), transgender women (TGW), and cisgender women. A decision-analytic model was developed to assess the lifetime cost-effectiveness of CAB-LA compared with FTC/TDF for HIV-1 PrEP in the US.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
